echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Plant Extracts News > Reissue of shares of Rhine bio suggests that there will be ex right loss if the shares are missed

    Reissue of shares of Rhine bio suggests that there will be ex right loss if the shares are missed

    • Last Update: 2019-04-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On April 3, Rheinland Biology (002166) issued a share allotment announcement The company will allot 3 shares for every 10 shares to all shareholders April 8, 2019 is the equity registration date, and the share allotment price is 3.77 yuan / share, only 37.18% of the closing price on April 8 Investors who still hold shares on the date of equity registration will be subject to ex right loss if they do not participate in the allotment If all investors participate in the allotment, the ratio of loss of investors not participating in the allotment is about 14% based on the closing price on April 8 as the reference standard for calculating the ex right price And participating in the allotment can at least guarantee the stock market value unchanged when the right is removed; professionals believe that according to the current stock price trend, the stock price after the right removal is also expected to go out of the filling market, if investors do not participate in the allotment may face greater losses Under the background that the state listed "natural food additives, new technology development and production of natural flavors" and other encouraged investment projects in the industry guidance catalogue, the market space of natural plant extracts has become wider and wider, and has begun to show a rapid growth trend in recent years Rhine bio's IPO is obviously aimed at seizing the opportunity of industrial development and seizing the huge market space of plant extracts The study found that with the improvement of living standards, people's diet structure and lifestyle have changed significantly Diabetes, obesity, hypertension, hyperglycemia, hyperlipidemia and other "rich diseases" have become the main threat to global human health Due to the excessive intake of sugar, high incidence of diseases such as hypertension, diabetes, caries and so on are caused Global consumers' demand for low calorie, sugar free food and beverage and nutrition and health care products is greatly increased The trend of natural sweeteners replacing sugar is increasingly significant, especially stevioside market is maintaining rapid growth According to the market report data of persistence Market Research (PMR), the global stevioside market was about $347 million in 2014, and is expected to reach $565.2 million by 2020, with a compound annual growth rate of 8% According to the public information, Rhine bio is a company specializing in the research, development, production and sales of natural plant extracts It has a history of nearly 20 years since its establishment In 2015, 2016 and 2017, the company achieved operating revenues of 514.4712 million yuan, 571.4482 million yuan and 801.2627 million yuan, respectively The company is one of the standard setting enterprises in China's plant extraction industry It has a high reputation in China's plant extraction industry It is the vice president unit of China Medical Insurance chamber of Commerce and the director unit of Guangxi Luohanguo industrial technology innovation strategic alliance At present, Rhine biology has 50 national invention patents, hundreds of products developed by the technology center, and dozens of products have passed the strict test by independent foreign testing institutions The company is the first Chinese enterprise in China to obtain FDA gras certification of Siraitia grosvenorii extract and Stevia rebaudiana extract, and also the first Chinese enterprise to apply for EFSA certification of Siraitia grosvenorii extract According to the share allotment of Rhine bio, the implementation of the fund-raising project will further improve the strategic planning and layout of the company in the field of natural health products, open up the upstream of the industrial chain, fully guarantee the supply scale and quality of bulk raw materials, greatly improve the competitive advantage of the company's natural sweetener business in the market, and fight for the company to become a global leading natural sweetener enterprise Strategic goals lay a solid foundation.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.